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OBJECTIVES: Recently the LUNDEX index as a composite measure of therapeutic 
response and adherence on treatment was introduced to rheumatology.The objective 
of our study was to assess the cost-effectiveness of TNF-alpha blockers (inﬂiximab-
INF, adalimumab-ADA and etanercept-ETA) in Czech Republic based on real-world 
data from ATTRA registry. METHODS: Therapeutic response and the adherence data 
were derived from Czech registry of biologics in rheumatoid arthritis (ATTRA). The 
time horizon was 12 months. The response criterion used in this analysis was the 
remission based on EULAR deﬁnition (DAS28  2.6). The direct health care costs 
including the cost of administration during 12 months were calculated. RESULTS: 
Drug and administration costs for the payer during 12 months were 428,901 CZK 
(a16,437) for etanercept, 454,203 CZK (a17,467) for inﬂiximab and 455,270 CZK 
(a17,510) for adalimumab. For calculation of the cost per LUNDEX-response over 
12 months the total costs were divided by the LUNDEX-response. The results for each 
TNF-a blocker are shown in table as ETA: 0.83, 0.282, 0.23, 71,723EUR; INF: 0.78, 
0.129, 0.10, 174,670EUR; ADA: 0.81, 0.178, 0.14, 125,074EUR for Therapy adher-
ence, Proportion of patients in remission, LUNDEX response, Cost/LUNDEX per 12 
months where 1 EUR  26 CZK. The average cost per LUNDEX-responder month 
are were calculated by dividing the costs/LUNDEX per 12 months by 12. The results 
are a5977 for etanercept, a14,556 for inﬂiximab and a10,423 for adalimumab. CON-
CLUSIONS: The LUNDEX is useful tool for evaluating the effectiveness of TNF-alpha 
blockers in real-world clinical practice and biologics registries combining two impor-
tant dimensions (adherence and response). From the perspective of Czech registry 
ATTRA etanercept seems to be the most cost-effective option.
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OBJECTIVES: Oral bisphosphonates (OB) represent the standard treatments for 
osteoporosis, but despite their proven effectiveness in clinical trials, they have shown 
signiﬁcant problems with compliance in clinical practice. The objective of this paper 
is to study the cost-effectiveness (CE) of Zoledronic Acid (Zol) a molecule still belong-
ing to the category of bisphosphonates, but whose administration route is intravenous. 
Due to this circumstance, treatment with Zol potentially overcomes the limitations of 
OB, since patients are treated once a year with a single infusion. METHODS: We use 
a Bayesian Markov model and perform a CE analysis integrating evidence from dif-
ferent sources, such as published data on clinical outcomes and ofﬁcial records on 
population, mortality and morbidity; the costs considered are for hospitalisations, 
pharmacological treatment and rehabilitation. Uncertainty is propagated through the 
model using MCMC based algorithms. The validity of the results is checked using 
Probabilistic Sensitivity Analysis, summarised by means of the Cost-effectiveness 
acceptability curve (CEAC) and the Expected value of information (EVI). RESULTS: 
In all the 5 regions analysed, Zol tends to reduce the number of re-fractures (24% 
in Lombardia, with similar ﬁgures in the other regions), due to its higher compliance. 
Despite higher costs for treatment, Zol produces net savings in all the regions. The 
analysis of CEAC shows that the uncertainty related to the CE of Zol is limited in all 
the regions (with willingness to pay as low as a12,000, the posterior probability of 
CE reaches values as high as 0.96 in comparison with OB). The EVI analysis also 
shows that the value of acquiring additional information to limit uncertainty in the 
CE is limited. CONCLUSIONS: Zoledronic Acid proves to be an interesting alterna-
tive to OB, capable of overcoming their limitations in terms of compliance with 
treatment.onal information to limit uncertainty in the CE is limited.
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IN KNEE OSTEOARTHRITIS
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OBJECTIVES: This study aims to conduct a cost-effectiveness analysis of glucosamine 
sulphate treatment as compared to placebo in knee osteoarthritis from the Belgian 
health care system perspective. The economic evaluation investigates whether the drug 
acquisition costs of patients receiving glucosamine sulphate treatment are balanced 
by a lower incidence of total knee replacement and reduced hospitalization costs. 
METHODS: The study collected Belgian cost data and derived effectiveness data from 
a long-term follow-up of patients with knee osteoarthritis. Two randomised, placebo-
controlled, double-blind trials compared patients who had received oral glucosamine 
sulphate 1500 mg once-a-day for up to 3 years with patients who had received 
placebo. Patients who had participated in these two trials and who had received at 
least one year of treatment were enrolled in a retrospective assessment of the incidence 
of total knee replacement during a ﬁve-year follow-up period. The price year was 
2006. RESULTS: The sample consisted of 131 patients who had formerly received 
placebo and 144 patients who had formerly received glucosamine sulphate. The 
number of patients undergoing total knee replacement during the 5-year follow-up 
amounted to 19 patients (14.5%) in the former placebo group and 9 patients (6.3%) 
in the former glucosamine sulphate group. Health care costs per patient amounted to 
a1103 in the former placebo group and a901 in the former glucosamine sulphate 
group. CONCLUSIONS: Treatment of knee osteoarthritis with glucosamine sulphate 
for at least one year and up to three years was associated with a lower incidence of 
total knee replacement and lower health care costs over an observation period of eight 
years as compared with placebo.
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OBJECTIVES: Vertebral compression fractures (VCFs) in osteoporotic patients are 
associated with chronic pain, a reduction in health-related quality of life (QoL) and 
high health care costs. Balloon Kyphoplasty (BKP) is a minimally invasive procedure 
that has resulted in pain relief, vertebral body height-restoration, and improved physi-
cal functioning in patients with symptomatic VCFs. BKP was shown to improve 
health-related QoL in a 12-month analysis of a randomised phase-III trial. The objec-
tive of this study was to estimate the cost-effectiveness of BKP compared to non-
 surgical management in a UK setting. METHODS: A Markov cost-effectiveness model 
was constructed to evaluate BKP after painful hospitalised VCFs from a health care 
perspective. The model was populated with relevant epidemiology and cost data. It 
was assumed that QoL-beneﬁts found at 12 months linearly approached zero during 
the following 24 months and that patients receiving BKP required 6 less hospital bed-
days compared to patients given non-surgical management. No reduction of future 
fracture risk was assumed. The cost of the BKP devices and procedure was £2690 and 
£1400, respectively. A 43% reduction in mortality during the ﬁrst year after the pro-
cedure was explored in sensitivity analysis. RESULTS: The procedure was in the 
base-case associated with estimated QALY-gains of 0.17 and cost/QALY of £8800 in 
70 year old patients. Results marginally deteriorated with increasing age at the time 
of surgery due to higher mortality and fracture rates, both of which shorten the 
accrued beneﬁt of BKP. Inclusion of a mortality reduction resulted in 0.448 life years 
gained per patient and a cost/QALY of £4600. The results were also sensitive to 
assumptions about the cost of the procedure, avoided length of hospital-stay and 
persistence of balloon kyphoplasty-related QoL-beneﬁts. CONCLUSIONS: The 
results indicate that BKP provides a cost-effective alternative for treating patients with 
hospitalised VCFs in a UK-setting.
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OBJECTIVES: The primary objective was to determine and analyze the indirect costs 
associated with rheumatoid arthritis (RA) before and after six months of treatment 
with TNFA blockers. The secondary objective was to evaluate the impact of health 
condition improvement, assessed using Health Assessment Questionnaire (HAQ) ques-
tionnaire, on the indirect costs after treatment. METHODS: The study was a retro-
spective-longitudinal cost analysis and reﬂects the common practice of using anti-TNFA 
drugs. Indirect costs before and after anti-TNFA therapy initiation were recorded then 
compared in order to estimate the decrease in indirect costs due to the use of TNFA 
blockers. Patients were asked to provide information on working days lost in the six 
months preceding the enrollment; and followed up for six months after starting anti-
TNFA therapy. Costs were quantiﬁed using Human Capital Approach method and 
considering the societal perspective. A zero inﬂated negative binomial model was 
adopted to evaluate the effect of HAQ improvement adjusting by demographic data 
and other factors that inﬂuence indirect costs RESULTS: The mean cost per month 
per patient before and after the starting therapy with anti-TNFA was a343.18 and 
a58.92, respectively (p  0.0001). HAQ improvement was to be associated with a 
decreasing risk to incur indirect costs. CONCLUSIONS: Our data links the indirect 
costs due to the disease mostly to its impact on function and degree of disability of 
the patients. Our results showed that anti-TNFA therapy is effective even in the short 
term this is mainly attributable to the dramatic improvement in functional status and, 
consequently, in quality of life. This improvement can be translated in monetary terms. 
Results suggest that anti-TNFA can dramatically decrease the indirect costs of RA, 
and the amount of saved resources will be increased if patients are promptly treated 
thus avoiding disease progression.
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OBJECTIVES: To quantify potential cost savings and quality adjusted life year 
(QALY) gains of improving the blood pressure (BP) proﬁle of non-steroidal anti 
inﬂammatory drugs (NSAIDs). METHODS: Increasing attention has been paid to the 
